HCC combined with microvascular tumor thrombus
Conditions
Interventions
experimental group :anti-PD-1 200mg Q3W,6mongths
Sponsors
The Third Affiliated Hospital of the Second Military Medical University of the Chinese people's Liberation Army
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged from 20 to 70 years old with liver cancer complicated with mivi (stage I) can receive surgical treatment; 2. Two senior liver surgeons considered that the tumor was resectable, and there were no extrahepatic metastasis and adjacent organ invasion before operation; 3. Patients with ehbh-mvi score > 4; 4. For patients with ECoG score of 0-1, child grade A or grade B of liver function in screening period was 7 points; 5. Patients with HCC confirmed by pathology; 6. Patients without significant heart, lung and kidney dysfunction were not infected with HCV, HIV or syphilis; 7. All patients should sign informed consent when they are selected.
Exclusion criteria
Exclusion criteria: 1. Patients with intrahepatic or extrahepatic recurrence within 1 month after operation; 2. Patients with intolerable side effects or clinical accidents after the first treatment with sindilimab; 3. Patients with unstable angina pectoris, symptomatic congestive heart failure, severe arrhythmia, myocardial infarction in the past 6 months and QT interval prolongation (> 450ms); 4. Patients with other malignant tumors in the last 5 years; 5. Patients can not accept follow-up or are participating in other clinical trials; 6. Pregnant women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| RFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| OS;PFS;Change of AFP; | — |
Countries
China
Contacts
Public ContactKang Wang, Shuqun Cheng
The Third Affiliated Hospital of the Second Military Medical University of the Chinese people's Liberation Army
Outcome results
None listed